

BOTOX
MEAN CHANGE IN NUMBER OF HEADACHES PER 30-DAY PERIOD AFTER ADMINISTRATION OF BOTOX
MEAN CHANGE IN NUMBER OF HEADACHES
DAYS AFTER ENROLLMENT
0
-1
-2
-3
-4
-5
-6
-7
-8
0
30
60
90
120
150
180
210
240
270
-0.8
-3.3
-4.1
-3.9
-4.6
-6.3
-6.1
-6.5
-7.1
-7.2

FIG. 1



BOTOX
MEAN CHANGE IN NUMBER OF DAYS WITH ACUTE HEADACHE MEDICATION PER 30-DAY PERIOD AFTER ADMINISTRATION OF BOTOX
MEAN CHANGE IN NUMBER OF DAYS
0
-2
-4
-6
-8
-10
-12
-0.7
-3.6
-5.0
-4.9
-5.0
-6.2
-6.0
-6.9
-7.2
-6.8
0
30
60
90
120
150
180
210
240
270
DAYS AFTER ENROLLMENT

FIG. 2



% OF PATIENTS WITH NARCOTICS ACUTE HEADACHE MEDICATION USE PER 30-DAY PERIOD AFTER ADMINISTRATION OF BOTOX OR Placebo
BOTOX (n=173)
Placebo (n=182)
% OF PATIENTS
100
90
80
70
60
50
40
30
20
10
0
34 33
30 29
30 29
30 29
27 29
25 29
25 24
26 17
27 17
26 13
Baseline
0
30
60
90
120
150
180
210
DAYS AFTER ENROLLMENT

FIG. 3



BOTOX (n=39)
% OF PATIENTS WITH ACUTE HEADACHE MEDICATION OVERUSE
(>10 DAYS) PER 30-DAY PERIOD AFTER ADMINISTRATION OF BOTOX
% OF PATIENTS
100
90
80
70
60
50
40
30
20
10
0
82
39
36
27
27
38
24
20
15
10
5
Baseline
0
30
60
90
120
150
180
210
240
270
DAYS AFTER ENROLLMENT

FIG. 4



% OF PATIENTS WITH TRIPTANS ACUTE HEADACHE MEDICATION OVERUSE (>10 DAYS) PER 30-DAY PERIOD AFTER ADMINISTRATION OF BOTOX OR Placebo
BOTOX (n=173)
Placebo (n=182)
% OF PATIENTS
100
90
80
70
60
50
40
30
20
10
0
Baseline
0
30
60
90
120
150
180
210
DAYS AFTER ENROLLMENT
23 24
21 19
17 20
13 14
16 17
10 22
12 18
10 19
11 23

FIG. 5



Mean Change in Number of Headaches per 30-Day Period
(≥15 days AND ≥ 2 days/week) (pooled strata)
BOTOX (n=82)
Placebo (n=105)
Without MOU
With MOU
BOTOX (n=91)
Placebo (n=77)
*P≤0.05
Mean Change in Number of Headaches
0
-2
-4
-6
-8
-10
-12
0 30 60 90 120 150 180 210 240 270
2.0
3.0
2.6
3.9
4.5
5.4
5.6
4.6
Baseline: BOTOX=11.7, Placebo=11.1
Baseline: BOTOX=15.2, Placebo=14.9

FIG. 6



Mean Change from Baseline in Number of Headaches per 30-Day period (pooled strata)
BOTOX (n=56)
Placebo (n=71)
*P=0.030
With Prophylaxis
Mean Change in Number of Headaches
0
-2
-4
-6
-8
-10
-12
0 30 60 90 120 150 180 210 240 270
2.7
Baseline: BOTOX=12.4, Placebo=12.5
BOTOX (n=117)
Placebo (n=111)
*P≤0.032
Without Prophylaxis
2.2
2.5
2.6
3.3
3.9
4.2
Baseline: BOTOX=141, Placebo=12.9

FIG. 7



Mean Change from Baseline in Number of Headaches per 30-Day period (pooled strata)
BOTOX (n=117)
Placebo (n=111)
*P≤0.032
BOTOX (n=63)
Placebo (n=44)
*P≤0.045
With Prophylaxis
With MOU, Without Prophylaxis
Mean Change in Number of Headaches
0
-2
-4
-6
-8
-10
-12
0 30 60 90 120 150 180 210 240 270
2.2 2.5 2.6 3.3 3.9 4.2
2.5 3.1 5.5 4.5 6.8
Baseline: BOTOX=14.1, Placebo=12.9
Baseline: BOTOX=15.5, Placebo=14.3

FIG. 8



Mean Change from Baseline in Number of Headaches per 30-Day period (pooled strata)
BOTOX (n=56)
Placebo (n=71)
*P=0.030
Without MOU, Without Prophylaxis
Mean Change in Number of Headaches
0
-2
-4
-6
-8
-10
-12
0 30 60 90 120 150 180 210 240 270
2.7
Baseline: BOTOX=12.3, Placebo=12.0
BOTOX (n=63)
Placebo (n=44)
*P≤0.045
With MOU, Without Prophylaxis
2.5 3.1
5.5
4.5
6.8
Baseline: BOTOX=15.5, Placebo=14.3

FIG. 9



BOTOX (n=173)
Placebo (n=182)
*P=0.046
Incidence of Patients with Any Opioid Acute Headache Medication Use per 30-Day period (pooled strata)
% of Patients
Days after Enrollment
Baseline
0
30
60
90
120
150
180
210
240
270
34 33
30 29
30 29
27 29
25 29
25 24
26 17
27 17
26 13
27 17
27 17
26 17

FIG. 10



Mean Change from Baseline in Number of Headaches With & Without Baseline Triptan MOU per 30-Day Period (pooled strata)
BOTOX (n=30)
Placebo (n=36)
BOTOX (n=143)
Placebo (n=146)
With Triptan MOU
Without Triptan MOU
Mean Change in Number of Headaches
0
-2
-4
-6
-8
-10
-12
-14
0 30 60 90 120 150 180 210 240 270
Baseline: BOTOX=17.7, Placebo=16.1
Baseline: BOTOX=12.7, Placebo=11.9

FIG. 11



Mean Change from Baseline in Number of Days with Acute Analgesic Medication Use with & without Baseline Triptan MOU per 30-Day Period (pooled strata)
BOTOX (n=30)
Placebo (n=36)
BOTOX (n=143)
Placebo (n=146)
With Triptan MOU
Without Triptan MOU
Mean Change in Number of Days
0
-2
-4
-6
-8
-10
-12
-14
0 30 60 90 120 150 180 210 240 270
*
Baseline: BOTOX=19.9, Placebo=19.8
Baseline: BOTOX=14.3, Placebo=12.6

FIG. 12




Illustration of the Face and Sites to Inject for Treatments 1, 2, 3 and 4.

FIG. 13



Mean Change from Baseline in Frequency of Headaches per 30-Day Period Placebo Non-responders (A) and Placebo Responders (B)
PNR BOTOX (n=134)
PNR Placebo (n=145)
pr BOTOX (n=39)
pr Placebo (n=37)
A
B
Days after Enrollment
Days after Enrollment
PNR = placebo non-responders, pr = placebo responders.
Baseline: PNR BOTOX = 13.1, PNR placebo = 12.8 , pr BOTOX = 15.0, pr placebo = 12.3 headaches
*p≤0.050
Arrows indicate when dosing occurred (post placebo run-in)

FIG. 14




Mean Change from Baseline in the Frequency of Headaches per 30-day Period; Pooled Population
BOTOX (n=173)
Placebo (n=182)
0
-1
-2
-3
-4
-5
-6
-7
-8
-9
0
30
60
90
120
150
180
210
240
270
Days after Enrollment
-1.0
-1.9
-2.7
-3.2
-3.7
-3.6
-3.7
-4.6
-4.2
-5.1
-5.4
1.4
1.5
1.8
2.3
3.4
3.2
2.8
2.6
-4.1
-4.8
-4.9
-5.4
-6.9
-7.1
-7.4
-7.9
-8.0
*
*
*
*
*
*
Baseline: BOTOX=13.5, Placebo=12.7 headaches.
*p≤0.050
Arrows indicate when dosing occurred (post placebo run-in)

FIG. 15



Baseline: With prophylaxis BOTOX = 14.9, days with prophylaxis placebo = 14.8 days, without prophylaxis BOTOX =15.5 days, without prophylaxis placebo = 13.5 days of use.

*$p \leq 0.050$

Arrows indicate when dosing occurred (post placebo run-in)

FIG. 16



Supine
Sitting
A Corrugator
ESD: 10 U (in 2 sites)
B Procerus
ESD: 10 U (in 1 site)
C Frontalis
ESD: 20 U (in 4 sites)
D Temporalis
ESD: 20 U (in 4 sites)
FTP: 10 U (in 2 additional sites)
E Occipitalis
ESD: 20 U (in 4 sites)
FTP: 10 U (in 2 additional sites)
F Lateral Occipital
ESD: 20 U (in 4 sites)
G Temporalis
ESD: 20 U (in 4 sites)
FTP: 10 U (in 2 additional sites)
*0.1 mL = 10 U (and ESD = front site, hind sites; FTP = optional follow-the-pain sites.
The anatomic injection sites follow cutaneous distributions and areas innervated by the first division of the trigeminal nerve and the second cervical nerve.

FIG. 17